Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis

ConclusionsCompared with BP group, denosumab group displayed significantly increased H-BMD at 6  months, while L-BMD and H-BMD were significantly increased for 24 months in both groups. Thus, regardless of BP pre-treatment, denosumab could be a good agent in OP with RA.
Source: Archives of Orthopaedic and Trauma Surgery - Category: Orthopaedics Source Type: research